Current News

RSS

Buzzwords of the day

14 May 2008

• Bone Medical further positive results from oral osteoporosis drug trial (14 May 2008)
  Bone Medical oral drug appears to match the injectable alternative
  Bone Medical Limited has obtained important positive data on blood levels of peptide from testing its oral parathyroid hormone (PTH) CaPTHymone(TM) osteoporosis product. These results are from a second clinical trial of CaPTHymone(TM) conducted ...
  
  more information
   
• NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients (14 May 2008)
  NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating ...
  
  more information
   
• Selvita appoints Dr. Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board (14 May 2008)
  Selvita Sp. z o.o. announced the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita's drug research projects. After the first experience in 2002 as a ...
  
  more information
   
• Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation (14 May 2008)
  Intercell AG and Iomai Corporation announced that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value of approximately USD 189 million ...
  
  more information
   
• Affimed validates antibody target for cancer metastasis (14 May 2008)
  Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of ...
  
  more information
   

13 May 2008

• FivePrime Reports Discovery of IL-34 (13 May 2008)
  Science, researchers at Five Prime Therapeutics, Inc. report the discovery of Interleukin34, a novel cytokine, as well as the identification of an IL-34 receptor. "This work is a textbook example of how our platform enables us to make important ...
  
  more information
   
• KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist (13 May 2008)
  KeyNeurotek Pharmaceuticals AG announced positive results of a Phase I study with its cannabinoid receptor-agonist KN38-7271. KN38-7271 is being developed for the treatment of patients suffering from acute neurodegenerative incidents like a ...
  
  more information
   
• Cytopia announces novel anti-cancer drug development collaboration (13 May 2008)
  Cytopia Limited announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a ...
  
  more information
   
• Berkeley Researchers Identify Photosynthetic Dimmer Switch (13 May 2008)
  In a study of the molecular mechanisms by which plants protect themselves from oxidation damage should they absorb too much sunlight during photosynthesis, a team of researchers has discovered a molecular "dimmer switch" that helps control the ...
  
  more information
   
• Quest PharmaTech Signs Agreement to sell Bionex Technology (13 May 2008)
  Quest PharmaTech Inc. announced that it has signed a Technology Transfer Agreement with Peking Marvel Cleansing Supplies Co., Ltd., a China-based company, to sell its interest in the Bionex Technology. Peking Marvel is anticipated to be ...
  
  more information